Moreover, novel multiagonist peptides that combine GLP-1 with GIP, glucagon, or amylin activity may synergistically target central circuits governing appetite, cognition, and affect, thereby expanding the therapeutic spectrum of incretin-based agents [91,93]
Compared to individual GLP- 1 receptor agonists, its action on GIP and GLP- 1 receptors improves appetite control and metabolic function, indicating higher efficacy [117]
There is no formal definition, but in the athlete community, microdosing typically means staying at or below 0.5mg weekly semaglutide rather than titrating up to the standard 1.7mg or 2.4mg therapeutic doses
However, severe vomiting, inability to keep fluids down, or significant dehydration should prompt medical advice before continuing